The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and Computational Analysis
Open accessAbstract
Electrophilic probes that covalently modify a cysteine thiol often show enhanced pharmacological potency and selectivity. Although reversible Michael acceptors have been reported, the structural requirements for reversibility are poorly understood. Here, we report a novel class of acrylonitrile-based Michael acceptors, activated by aryl or heteroaryl electron-withdrawing groups. We demonstrate that thiol adducts of these acrylonitriles undergo β-elimination at rates that span more than 3 orders of magnitude. These rates correlate inversely with the computed proton affinity of the corresponding carbanions, enabling the intrinsic reversibility of the thiol-Michael reaction to be tuned in a predictable manner. We apply these principles to the design of new reversible covalent kinase inhibitors with improved properties. A cocrystal structure of one such inhibitor reveals specific noncovalent interactions between the 1,2,4-triazole activating group and the kinase. Our experimental and computational study enables the design of new Michael acceptors, expanding the palette of reversible, cysteine-targeted electrophiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
Fleming, F. F., Yao, L., Ravikumar, P. C., Funk, L., & Shook, B. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100762r · Cited by 1,754
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 493
Self-citationThe discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Gauthier, J. Y., Chauret, N., Cromlish, W., Desmarais, S., Duong, L. T., Falgueyret, J.-P., Kimmel, D. B., Lamontagne, S., Léger, S., LeRiche, T., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.047 · Cited by 477
Managing the challenge of chemically reactive metabolites in drug development
Park, B. K., Boobis, A., Clarke, S., Goldring, C. E. P., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3408 · Cited by 462
Structure and Stereochemistry of the Active Metabolite of Clopidogrel
Pereillo, J.-M., Maftouh, M., Andrieu, A., Uzabiaga, M.-F., Fedeli, O., Savi, P., Pascal, M., Herbert, J.-M., Maffrand, J.-P., & Picard, C. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1288 · Cited by 460
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole
Olbe, L., Carlsson, E., & Lindberg, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1010 · Cited by 418
Covalent Modifiers: An Orthogonal Approach to Drug Design
Potashman, M. H., & Duggan, M. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8008597 · Cited by 346
Schwartz, P. A., Kuzmic, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C., Nagata, A., Ryan, K., Feng, J., Dalvie, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313733111 · Cited by 281
Idiosyncratic Drug Reactions: Past, Present, and Future
Uetrecht, J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700186p · Cited by 257
Lin, C., Kwong, A., & Perni, R. (2006) · Infectious Disorders - Drug Targets · doi:10.2174/187152606776056706 · Cited by 243
Protein Damage by Reactive Electrophiles: Targets and Consequences
Liebler, D. C. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700235t · Cited by 237
Applying Mechanisms of Chemical Toxicity to Predict Drug Safety
Guengerich, F. P., & MacDonald, J. S. (2007) · Chemical Research in Toxicology · doi:10.1021/tx600260a · Cited by 231
Smith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193
Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors
Miller, R. M., Paavilainen, V. O., Krishnan, S., Serafimova, I. M., & Taunton, J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja401221b · Cited by 191
Self-citationA Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases
Kathman, S. G., Xu, Z., & Statsyuk, A. V. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500345q · Cited by 170
Patch, R. J., Searle, L. L., Kim, A. J., De, D., Zhu, X., Askari, H. B., O’Neill, J. C., Abad, M. C., Rentzeperis, D., Liu, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101063h · Cited by 141
Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation
Metzler, W. J., Yanchunas, J., Weigelt, C. A., Kish, K., Klei, H. E., Xie, D., Zhang, Y., Corbett, M. J., Tamura, J. K., He, B., et al. (2008) · Protein Science · doi:10.1110/ps.073253208 · Cited by 132
SAR and Mode of Action of Novel Non-Nucleoside Inhibitors of Hepatitis C NS5b RNA Polymerase
Powers, J. P., Piper, D. E., Li, Y., Mayorga, V., Anzola, J. V., Chen, J., Jaén, J. C., Lee, G., Liu, J., Peterson, M. G., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050859x · Cited by 131
Development of Nitrile-Based Peptidic Inhibitors of Cysteine Cathepsins
Frizler, M., Stirnberg, M., Sisay, M. T., et al. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790725452 · Cited by 120
Reversibility of Covalent Electrophile−Protein Adducts and Chemical Toxicity
Lin, D., Saleh, S., & Liebler, D. C. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800248x · Cited by 114
Couch, R. D., Browning, R. G., Honda, T., Gribble, G. W., Wright, D. L., Sporn, M. B., & Anderson, A. C. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.031 · Cited by 110
Reversible Michael Additions: Covalent Inhibitors and Prodrugs
Johansson, M. H. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575112091330 · Cited by 96
Equilibrium reactions of n-butanethiol with some conjugated heteroenoid compounds
Pritchard, R. B., Lough, C. E., Currie, D. J., & Holmes, H. L. (1968) · Canadian Journal of Chemistry · doi:10.1139/v68-128 · Cited by 50
Jensen, K. S., Pedersen, J. T., Winther, J. R., & Teilum, K. (2014) · Biochemistry · doi:10.1021/bi4016633 · Cited by 44
Cited by
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335
Flanagan, M. E., Abramite, J. A., Anderson, D. P., Aulabaugh, A., Dahal, U. P., Gilbert, A. M., Li, C., Montgomery, J., Oppenheimer, S. R., Ryder, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501412a · Cited by 320
Metadata
- Authors
- Krishnan, S., Miller, R. M., Tian, B., Mullins, R. D., Jacobson, M. P., & Taunton, J.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-09-02
- Volume
- 136
- Issue
- 36
- Pages
- 12624-12630
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W2048072131
- Cited by
- 260
- References
- 30
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.